Running head: popPK model of ketamine and three major metabolites
INTRODUCTION
(R,S)-Ketamine ((R,S)-Ket; Figure 1 ), is a chiral phencyclidine derivative that was initially developed as an anesthetic agent and which is currently being studied in the treatment of pain and depression [1, 2] . Sub-anesthetic doses of (R,S)-Ket have been successfully used in the treatment of patients with complex regional pain syndrome (CRPS), c.f. [3, 4] , postoperative pain in opioid tolerant patients [5] , in emergency room treatments [6] and in patients suffering from treatment-resistant bipolar depression [7] [8] [9] .
In the USA, Ket is used as a racemic (50:50) mixture of (R)-Ket and (S)-Ket; however, the administration of the single isomer, (S)-Ket, is effective in the treatment of CRPS [10] [11] [12] .
After administration, (R,S)-Ket is extensively N-demethylated to norketamine ((R,S)-norKet; Figure 1 ), which has anesthetic [13] and antinociceptive properties [14, 15] and is considered as the "active" metabolite. Figure 1 ), [16, 17] . An early study of the anesthetic activity of a key HNK metabolite, (2S,6S;2R,6R)-HNK, indicated that this compound did not produce anesthesia in the rat [13] , and there has been no subsequent characterization of the pharmacological activity of this metabolite, any of the other hydroxylated metabolites of Ket and norKet. However, recent work in our laboratories has demonstrated that (R,S)-DHNK is a potent inhibitor of the α7-nicotinic acetylcholine receptor and the data suggest that this metabolite may play a role in Ket clinical effects (unpublished data).
The pharmacokinetics of (R,S)-Ket, (R)-Ket and (S)-Ket have been extensively studied in volunteers and patients after the administration of anesthetic and sub-anesthetic doses of (R,S)-Ket and sub-anesthetic doses of (S)-Ket, c.f [11, [18] [19] [20] [21] [22] . Since (R,S)-norKet was identified as the "active" metabolite, these studies have often included the determination of the pharmacokinetic profiles of (R,S)-norKet or the separate enantiomers, but not the HK, HNK or DHNK metabolites. However, significant plasma concentrations of (2S,6S;2R,6R)-HNK were detected in the rat following administration of (R,S)-Ket or (R,S)-norKet [13] and (R)-and (S)-DHNK were identified in plasma samples obtained from patients [23] and rats [24] receiving (R,S)-Ket and in Shetland ponies after administration of (R,S)-Ket or (S)-Ket [25,26]. All of the major metabolites of (R,S)-Ket, with the exception of (2S,6R;2R,6S)-HK, have been identified in urine samples obtained from volunteers who received a single 50 mg oral dose of (R,S)-Ket [27] and in the plasma and urine of CRPS patients receiving a continuous 5-day infusion of (R,S)-Ket [28] . 
METHODS

Patient samples
The plasma samples analyzed in this study were obtained during a previously reported study of the effect of (R,S)-Ket in the treatment of treatment-resistant bipolar depression [8] . In brief: After obtaining informed consent, the patients were entered into a randomized double-blind crossover study in which they received a 40 min infusion of 50 ml of either 0.9% saline solution or a 0.5 mg/kg dose of (R,S)-Ket hydrochloride. There was a 2-week period between infusions. Plasma samples were collected prior to the initiation of the infusion, at 40 min (end of the infusion), 80 min, 110 min, 230 min and on Days 1, 2 and 3 post-infusion and frozen at -80 ºC until analysis. During the course of the study the patients were required to take either lithium or valproate within a specified range and no other psychotropic medications were allowed. 
Bioanlaytical methods
The plasma concentrations of (R)-Ket, (S)-Ket, (R)-norKet, (S)-norKet, (R)-DHNK, (S)-DHNK, (2S,6S;2R,6R)-HNK, (2S,6S;2R,6R)-HK and (2S,6R
;2R,6S)-HK were determined using a previously described achiral-chiral liquid chromatography -mass spectrometry method [28] that was revalidated for the lower plasma concentrations observed in this study. The chromatographic experiments were carried out on a Shimadzu Prominence HPLC system (Shimadzu, Columbia, MD, USA) and total analyte concentrations were determined using an Eclipse XDB-C 18 (Applied Biosystems). Positive electrospray ionization data were acquired using multiple reaction monitoring (MRM) and quantification was accomplished using area ratios calculated using D 4 -(R,S)-Ket as the internal standard, where the concentration of the internal standard was set at 50 ng/ml.
Calibration curves and quality control standards were prepared using the racemic mixtures of the analytes. The 8-point calibration curves used to measure (R,S)-Ket and (R,S)-DHNK ranged from 3.9 to 500 ng/ml and the calibration curves used to measure 
Pharmacokinetic model
(R,S)-Ket was administered as a constant rate infusion (K 0 ). The model structure for each enantiomer is identical, and a schematic of the final pharmacokinetic model is shown in Figure 2 . The distribution of (S)-Ket was described by a central volume (V 1 s) and two peripheral compartments (A 2 s, A 3 s) and defined by the following system of equations: ( ) 
Data analysis
All measurements of (R)-and (S)-enantiomers for parent drug and metabolites were 
RESULTS
Subject characteristics
The subject population in this study included 6 females and 3 males whose age ranged from 23 to 62 yr (mean 46 ± 15 yr), weight from 51 to 118 kg (mean 90 ± 19 kg), and body mass index from 19 to 39 (mean 31 ± 6). All subjects were diagnosed with treatment-resistant bipolar depression, and additional study details have been previously published [8] .
Plasma concentrations of the stereosiomers of Ket and its metabolites
The achiral-chiral analytical method used in this study detected measurable quantities of This is consistent with the observation that (R)-DHNK was the predominate urinary metabolite in samples obtained from CRPS patients treated with a 5-day infusion of (R,S)-Ket [28] .
The time-course of (R)-and (S)-Ket and corresponding metabolite concentrations in a representative subject are shown in Figure 6 , and individual model predicted profiles 
